At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,167 enrolled
Drug / intervention
Epoetin betadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study to Evaluate Treatment of Symptomatic Anemia in Patients With Malignancies Receiving Chemo- and NeoRecormon-Therapy
In Brief
An observational study evaluating Epoetin beta for Anemia. Completed, enrolled 1,167 participants across 42 sites.
Detailed Summary
This observational study will evaluate the efficacy and safety of epoetin beta (NeoRecormon) in participants with symptomatic anemia and cancer receiving chemotherapy. Participants receiving NeoRecormon once weekly in accordance with the Summary of Product Characteristics will be followed for 4 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesHungary
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
Primary CompletionOct 2009
First PostedMar 2013
TodayJul 2026
First PostedMar 12, 2013
Enrollment StartMar 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.3 years ago
Interventions
Epoetin betadrug
Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.